Plain-English translation of NCT06523530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether goserelin acetate, a medication that creates a temporary menopause-like state by stopping menstruation, can reduce fatty liver disease in women with endometriosis. Researchers believe that the loss of estrogen during menopause may contribute to fat building up in the liver, and this medication offers a way to study that connection. About 62 women with endometriosis will either receive the medication or serve as a comparison group.
Fatty liver disease is very common and affects millions of people worldwide, but there are few effective treatments for it. Studies suggest that menopause and the loss of estrogen may play a role in developing this condition, but this hasn't been proven in human studies yet. This trial will help doctors understand whether controlling estrogen levels could be a way to treat or prevent fatty liver disease.
If you join this study, you will be assigned to either receive goserelin acetate injections after your endometriosis surgery or to be in a control group that does not receive this medication. Over the course of the trial, you will have visits where doctors monitor your liver health using blood tests and imaging scans to see if the medication affects fat buildup in your liver. The study will compare the two groups to understand whether stopping menstruation with this medication helps reduce fatty liver disease.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Greece